518 related articles for article (PubMed ID: 30270066)
1. Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice.
Vohnout B; Fábryová Ľ; Klabník A; Kadurová M; Bálinth K; Kozárová M; Bugáňová I; Sirotiaková J; Rašlová K
Atherosclerosis; 2018 Oct; 277():323-326. PubMed ID: 30270066
[TBL] [Abstract][Full Text] [Related]
2. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
[TBL] [Abstract][Full Text] [Related]
3. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD
Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
[TBL] [Abstract][Full Text] [Related]
4. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
Schmidt N; Dressel A; Grammer TB; Gouni-Berthold I; Julius U; Kassner U; Klose G; König C; Koenig W; Otte B; Parhofer KG; Reinhard W; Schatz U; Schunkert H; Steinhagen-Thiessen E; Vogt A; Laufs U; März W
Atherosclerosis; 2018 Oct; 277():314-322. PubMed ID: 30270065
[TBL] [Abstract][Full Text] [Related]
5. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
[TBL] [Abstract][Full Text] [Related]
6. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?
Kayikcioglu M; Tokgozoglu L; Dogan V; Ceyhan C; Tuncez A; Kutlu M; Onrat E; Alici G; Akbulut M; Celik A; Yesilbursa D; Sahin T; Sonmez A; Ozdogan O; Temizhan A; Kilic S; Bayram F; Sabuncu T; Coskun FY; Ildizli M; Durakoglugil E; Kirilmaz B; Yilmaz MB; Yigit Z; Yildirim AB; Gedikli O; Topcu S; Oğuz A; Demir M; Yenerçağ M; Yıldırır A; Demircan S; Yilmaz M; Kaynar LG; Aktan M; Durmus RB; Gokce C; Ozcebe Oİ; Akyol TK; Okutan H; Sag S; Gul OO; Salcioglu Z; Altunkeser BB; Kuku I; Yasar HY; Kurtoglu E; Kose MD; Demircioglu S; Pekkolay Z; Ilhan O; Can LH
Atherosclerosis; 2018 Oct; 277():341-346. PubMed ID: 30270069
[TBL] [Abstract][Full Text] [Related]
7. Familial hypercholesterolemia treatments: Guidelines and new therapies.
Raal FJ; Hovingh GK; Catapano AL
Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
[TBL] [Abstract][Full Text] [Related]
8. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
[TBL] [Abstract][Full Text] [Related]
9. Latvian registry of familial hypercholesterolemia: The first report of three-year results.
Latkovskis G; Saripo V; Gilis D; Nesterovics G; Upena-Roze A; Erglis A
Atherosclerosis; 2018 Oct; 277():347-354. PubMed ID: 30270070
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
Rizos CV; Elisaf MS; Skoumas I; Tziomalos K; Kotsis V; Rallidis L; Garoufi A; Athyros VG; Skalidis E; Kolovou G; Koutagiar I; Papagianni M; Antza C; Katsiki N; Ganotakis E; Liberopoulos EN
Atherosclerosis; 2018 Oct; 277():308-313. PubMed ID: 30270064
[TBL] [Abstract][Full Text] [Related]
11. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E;
Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
[TBL] [Abstract][Full Text] [Related]
12. Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.
Brunham LR; Ruel I; Khoury E; Hegele RA; Couture P; Bergeron J; Baass A; Dufour R; Francis GA; Cermakova L; Mancini GBJ; Brophy JM; Brisson D; Gaudet D; Genest J
Atherosclerosis; 2018 Oct; 277():419-424. PubMed ID: 30270080
[TBL] [Abstract][Full Text] [Related]
13. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
Miname MH; Santos RD
Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
[TBL] [Abstract][Full Text] [Related]
14. Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics.
Chua YA; Nazli SA; Rosman A; Kasim SS; Ibrahim KS; Md Radzi AB; Mohd Kasim NA; Nawawi H
J Atheroscler Thromb; 2023 Oct; 30(10):1317-1326. PubMed ID: 36567112
[TBL] [Abstract][Full Text] [Related]
15. A 10-year experience using combined lipid-lowering pharmacotherapy in children and adolescents.
Araujo MB; Pacce MS
J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1285-1291. PubMed ID: 27718491
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
Yamashita S; Masuda D; Harada-Shiba M; Arai H; Bujo H; Ishibashi S; Daida H; Koga N; Oikawa S
J Atheroscler Thromb; 2022 May; 29(5):608-638. PubMed ID: 33980760
[TBL] [Abstract][Full Text] [Related]
17. Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle.
Shek A; Alieva R; Kurbanov R; Hoshimov S; Nizamov U; Abdullaeva G; Nagay A
Atherosclerosis; 2018 Oct; 277():524-529. PubMed ID: 30270094
[TBL] [Abstract][Full Text] [Related]
18. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
Mata N; Alonso R; Badimón L; Padró T; Fuentes F; Muñiz O; Perez-Jiménez F; López-Miranda J; Díaz JL; Vidal JI; Barba A; Piedecausa M; Sanchez JF; Irigoyen L; Guallar E; Ordovas JM; Mata P
Lipids Health Dis; 2011 Jun; 10():94. PubMed ID: 21663647
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]